bijwerkingen van medicijnen ADHD MDD and anxietydisorders
Conditions
Interventions
None listed
Sponsors
Radiologie, Div I
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Exposed group: Females aged 23-30 years who have been treated with fluoxetine or another SSRI before age 16 (preferably at age 12-14) or treated at 23-30 years, presumably for treatment of moderate to severe MDD or anxiety disorder. Males aged 23-30 years who have been treated with methylphenidate before age 16 (preferably at age 10-12) or treated at age 23-30, presumably for treatment of ADHD. Unexposed groups: There will be two unexposed groups 23-30 years of age consisting of drugnaive subjects suffering from ADHD or MDD/anxiety disorder.
Exclusion criteria
Exclusion criteria: -IQ
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary study parameters/endpoints: - phMRI: difference in % change in ASL signal from baseline evoked by an acute pharmacological challenge between cases and control groups. - DTI: difference in FA and MD values between cases and control groups. - Resting state fMRI (rs-fMRI): difference in functional connectivity (FC) within specific (DA and 5-HT) neuronal networks | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary study parameters/endpoints: -fMRI: difference in task related BOLD signal between cases and control groups -Neuropsychological functioning: difference between cases and control groups in outcome of several well-validated neuropsychological (computer) tasks addressing emotional processing and impulsivity/behavioral inhibition compared to baseline measurements. -genetic and cortisol sampling | — |
Countries
Netherlands
Outcome results
None listed